September 12, 2011
Nippon Boehringer Ingelheim (NBI) announced on September 12 that it has started a multinational PIII study of the investigational oral tyrosine kinase inhibitor BIBF1120 for idiopathic pulmonary fibrosis (IPF) in Japan. IPF is a chronic, advanced, and unexplained pulmonary fibrosis...read more